Factor VII TRIZ Cases
- PD-1 B-cell Monitoring for Hemophilia A Tolerance Induction
PD-1 expression monitoring on B-cells predicts inhibitor development in hemophilia A patients, enabling optimized treatment regimens.
- Codon-Optimized Factor VIII Gene Therapy Vector Design
Segmenting Factor VIII into heavy and light chains with codon optimization improves viral packaging efficiency and reduces inhibitor antibody formation.
- Mini-FVIII Peptides for Hemophilia Treatment
Extracted peptide fragments retain procoagulant activity while reducing inhibitor antibody formation in hemophilia A therapy.
- VWF Nanofiltration Preserving Multimers at Low Pressure
Low pressure nanofiltration retains viral contaminants while preserving high molecular weight VWF multimers for therapeutic concentrates.
- Liver-Directed AAV Vectors for Hemophilia Gene Therapy
Minimized liver-specific promoters and codon optimization enable fVIII packaging within AAV capsids, resolving DNA size constraints.
- Calcium-Binding Z Domain Ligand for Mild Antibody Elution
Engineered Protein A-derived Z domain ligand enables calcium-dependent antibody elution at physiological pH, preventing aggregation caused by acidic conditions.
- VWF Fusion Protein O-Glycosylation for FVIII Half-Life Extension
An O-glycosylated VWF extension peptide extends FVIII half-life beyond 100 hours, reducing Hemophilia A treatment frequency.
- AAV Compositions for F8 Gene Correction Without Exogenous Nucleases
Replication-defective AAV vectors enable precise F8 gene editing via homologous recombination, avoiding off-target mutations from exogenous nucleases.
- Cleavable Linker Single Chain Fc Heterodimer Design
Segmenting the single chain Fc via enzymatic cleavage removes extraneous sequences, reducing immunogenicity while maintaining manufacturing efficiency.
- Modified Factor VIII Reducing NKT Cell Activation
Targeted amino acid substitutions in factor VIII eliminate CD1d binding motifs, preventing inhibitor formation and improving hemophilia A treatment reliability.
- Platelet-Targeted Gene Therapy for Hemophilia
Integrating clotting factor genes into hematopoietic stem cells eliminates inhibitor formation and reduces treatment costs.
- Truncated VWF Polypeptide FVIII Half-Life Extension
Truncated von Willebrand factor polypeptides bind Factor VIII to reduce catabolism and lower infection risk from frequent intravenous injections.